Acasti Pharma, Inc (ACST)

[errett]

oldB-----There always seems to be more than anyone expects in any trial-----sufficient evidence of a treatment effect doesn't disclose the degree of effect----especially relative to other products already on the market-----it also doesn't confirm the added benefit found in the earlier study i.e., lowering LDL and raising HDL-----the attribute that would help to distinguish Acasti from the competition in the marketplace-----there is also the issue of degree of elevated triglycerides in the tested patients----were they successful with the moderately high level patients or were the results based primarily on the very high level patient-----the existing drugs treat primarily very high (trigs) level patients-----we would love to see our drug work on everyone while it lowers LDL and raises HDL---that would be the "Home Run". jmo